Maier K, Frühmorgen P, Bode J C, Heller T, von Gaisberg U, Klotz U
Dtsch Med Wochenschr. 1985 Mar 8;110(10):363-8. doi: 10.1055/s-2008-1068828.
The effectiveness of oral 5-aminosalicylic acid (0.5 g t.i.d.) and of salazosulfapyridine (1.0 g t.i.d.) was compared in a randomized controlled study in two groups with 30 patients each with ulcerative colitis and with Crohn's disease. Persistent complaints within the first 5 days were treated with additional methyl-prednisolone (40 mg/d initially). After treatment for 8 weeks patients with ulcerative colitis showed morphologic remissions in 60% of the 5-aminosalicylic acid group and in 53% of the salazosulfapyridine group. Clinical improvement was achieved in 86% in both groups. Clinical improvement in Crohn's disease was seen in 87% of patients of the 5-aminosalicylic acid group and in 80% of the salazosulfapyridine group. This was evidenced by the significant fall (P = 0,0001) of the mean activity index. Additional steroid medication was nearly equal in both treatment groups. There were no side effects during treatment with 5-aminosalicylic acid. In contrast, salazosulfapyridine had to be withdrawn in four patients due to signs of intolerance. 5-Aminosalicylic acid can thus be considered a valuable alternative to conventional treatment on the basis of equal effectiveness as salazosulfapyridine and lack of undesirable side effects.
在一项随机对照研究中，对两组各30例溃疡性结肠炎和克罗恩病患者比较了口服5-氨基水杨酸（0.5克，每日三次）和柳氮磺胺吡啶（1.0克，每日三次）的疗效。最初5天内持续存在的症状用额外的甲基泼尼松龙（最初40毫克/天）治疗。治疗8周后，溃疡性结肠炎患者中，5-氨基水杨酸组60%出现形态学缓解，柳氮磺胺吡啶组为53%。两组临床改善率均为86%。克罗恩病患者中，5-氨基水杨酸组87%临床改善，柳氮磺胺吡啶组为80%。平均活动指数显著下降（P = 0.0001）证明了这一点。两个治疗组额外使用类固醇药物的情况几乎相同。5-氨基水杨酸治疗期间无副作用。相比之下，柳氮磺胺吡啶组有4例患者因不耐受症状而停药。因此，基于与柳氮磺胺吡啶同等的疗效以及无不良副作用，5-氨基水杨酸可被视为传统治疗的一种有价值的替代药物。
